Key Points
- Guardant Health director Musa Tariq sold 116 shares for $17,348.96 at an average price of $149.56 under a pre-arranged Rule 10b5-1 plan. He retained 11,717 shares after the sale.
- The company reported quarterly revenue of $360.98 million, up 36.1% year over year, and a loss of $0.29 per share—better than analysts’ expectations for a $0.75 loss.
- Analysts hold a “Moderate Buy” consensus rating, with an average price target of $190.88.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Alex Azar II sold 69 shares of the business's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $149.56, for a total transaction of $10,319.64. Following the transaction, the director owned 962 shares in the company, valued at approximately $143,876.72. This trade represents a 6.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Stock Performance
Shares of GH stock opened at $143.28 on Wednesday. Guardant Health, Inc. has a 52-week low of $74.55 and a 52-week high of $191.05. The company has a 50-day simple moving average of $167.94 and a two-hundred day simple moving average of $133.33. The company has a market capitalization of $19.38 billion, a price-to-earnings ratio of -38.93 and a beta of 1.67.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analysts' expectations of $350.72 million. During the same quarter last year, the business posted ($0.74) EPS. The company's quarterly revenue was up 36.1% on a year-over-year basis. On average, sell-side analysts forecast that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on GH. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $210.00 target price on shares of Guardant Health in a report on Thursday, September 10th. Guggenheim lifted their price target on Guardant Health from $190.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Barclays boosted their price objective on Guardant Health from $200.00 to $220.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Stephens upped their price objective on Guardant Health from $170.00 to $195.00 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. Finally, Rothschild & Co Redburn initiated coverage on Guardant Health in a research note on Tuesday, September 8th. They issued a "buy" rating and a $203.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $190.88.
Read Our Latest Stock Analysis on Guardant Health
Institutional Trading of Guardant Health
Hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC grew its position in shares of Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company's stock valued at $26,000 after acquiring an additional 151 shares during the period. NFSG Corp purchased a new stake in shares of Guardant Health during the 3rd quarter worth approximately $33,000. Jacobi Capital Management LLC purchased a new stake in shares of Guardant Health during the 3rd quarter worth approximately $35,000. Fulcrum Asset Management LLP bought a new stake in shares of Guardant Health in the 3rd quarter worth approximately $37,000. Finally, Hollencrest Capital Management bought a new stake in shares of Guardant Health in the 1st quarter worth approximately $41,000. Institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].